Clinical Research Directory
Browse clinical research sites, groups, and studies.
Safety and Tolerability of AT-0174 in Adults With Advanced Solid Tumors
Sponsor: Antido Therapeutics (Australia) Pty Ltd
Summary
This is a first-in-human, open-label, multicenter Phase 1 study of AT-0174, an investigational oral dual TDO2/IDO1 inhibitor. It is being conducted in adults with advanced solid tumors that have progressed on, or are not suitable for, standard therapy. The main goals are to evaluate the safety and tolerability of AT-0174 and to identify a recommended dose for further study.
Official title: A Phase I Study to Evaluate the Safety, Tolerability, Pharmacology, and Preliminary Efficacy of AT-0174 in Subjects With Advanced Solid Malignancies
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
26
Start Date
2023-11-15
Completion Date
2026-08-28
Last Updated
2026-10-21
Healthy Volunteers
No
Conditions
Interventions
AT-0174
Oral capsules taken once daily.
Locations (7)
Southside Cancer Care Centre
Miranda, New South Wales, Australia
Royal North Shore Hospital
St Leonards, New South Wales, Australia
Wollongong Hospital
Wollongong, New South Wales, Australia
Sunshine Coast University Private Hospital
Birtinya, Queensland, Australia
The Queen Elizabeth Hospital
Adelaide, South Australia, Australia
Grampians Health
Ballarat, Victoria, Australia
St Vincent's Hospital Melbourne
Fitzroy, Victoria, Australia